Search Medical Condition
Please enter condition
Please choose location

Starnberg-Percha, Germany Clinical Trials

A listing of Starnberg-Percha, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (119) clinical trials

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Background: Dual-chamber pacemaker therapy has become the mainstay for treating symptomatic sick sinus syndrome (SSS). This approach aims to results in a physiologic conduction pattern, while protecting against atrioventricular conduction anomalies. Smaller studies and subgroup analyses of larger trials suggest that ventricular stimulation associated with this treatment has adverse effects, ...

Phase

0.0 miles

Learn More »

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase.

Phase

1.8 miles

Learn More »

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of Humira for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice. The primary objectives of the PMOS are to explore changes in health related care utilization data by the evaluation of: - the number of ...

Phase N/A

1.8 miles

Learn More »

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

This is a randomized, double-blind, double-dummy, active comparator-controlled, parallel-group, multi-center study with variable treatment duration in approximately 900 patients with relapsing MS. The maximal treatment duration in the study for an individual patient will be 2.5 years. Eligible patients will be randomized to receive either experimental ofatumumab subcutaneous (sc) injections ...

Phase

2.17 miles

Learn More »

Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial

To investigate the effect of an anti-inflammatory therapy consisting of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan on the response rate in patients with relapsed or refractory or progressive multiple myeloma(MM). Phase I: to determine the lenalidomide dse for the phase II part (5 mg ...

Phase

2.17 miles

Learn More »

This study will enable patients receiving sorafenib (Nexavar) in the completed Bayer/Onyx sponsored clinical trials to continue treatment. During the entire course of the study, numerous patients will be treated with sorafenib. Involvement in this study will be depending on whether the patient benefits from the treatment or not, based ...

Phase

4.5 miles

Learn More »

Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)

Primary objective of this study is to assess the efficacy of durvalumab + tremelimumab + EP treatment compared with EP in terms of overall survival and progression-free survival. Appr. 795 patients will be randomized in a 1:1:1 ratio in a stratified manner according to the planned platinum-based therapy for Cycle ...

Phase

4.5 miles

Learn More »

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Phase

4.5 miles

Learn More »

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

M3814 is an investigational drug under evaluation for treatment of lung cancer. The purpose of the study is to assess the Safety and Efficacy of M3814 in combination with chemotherapy with SCLC ED.

Phase

4.5 miles

Learn More »

Tepotinib Phase II in NSCLC Harbouring MET Exon 14 (METex14) Skipping Alterations

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the ...

Phase

4.5 miles

Learn More »